Thrombocytopenia occurred in 40.7% of patients with smaller tumors but only in 11.3% of patients with larger tumors. Patients without thrombocytopenia had elevated GGTP and ALKP and lower bilirubin levels, regardless of tumor size, but they also had larger tumors within the large tumor tercile.
Introduction
Hepatocellular carcinoma (HCC) is thought to arise typically on a background of chronic hepatic inflammation due to hepatitis B or C, chronic alcoholism, a combination of these, or various metabolic liver disorders, including those associated with obesity. Given that the choice of treatment, and thus the prognosis, depends on early diagnosis, many studies have identified HCC risk factors among patients with chronic liver injury to aid in screening for those at greatest risk [1] [2] [3] . These factors include: male gender, age, cirrhosis with portal hypertension, and its surrogate marker thrombocytopenia [4] [5] [6] . We recently found a relationship between thrombocytopenia and HCC size, with lower platelet levels associated with smaller tumors [7, 8] . The current study was undertaken to further explore this relationship.
Results

Relation of Maximum Tumor Size to Plasma Platelet Levels
The relationship between plasma platelet levels and maximum tumor sizes in the whole cohort was examined ( fig. 1 a) , together with the linear regression line of the plot. An approximate relationship between increasing tumor size and increasing platelet levels was discerned. To further clarify this relationship, we trichotomized our data set into size terciles to more clearly separate patients on the outside 'wings' of the tumor size distribution ( fig. 1 b) . The tercile distributions showed a major density clustering of patients in the smallest tumor size tercile I at the lowest platelet levels ( fig. 1 b) . By contrast, tercile III patients with the largest tumors had a broader range of platelet distribution and a higher mean. The platelet level means were ( fig. 1 b, bottom) 142, 158, and 239 × 10 9 /l for patients in terciles I, II, and III, respectively (p = 0.0001). Significant differences were also found when terciles I versus II, I versus III, and II versus III were compared. Tercile III patients (90%) had much less cirrhosis than did tercile I patients (55%), as previously reported [7] . However, the terciles were similar with respect to alcoholism, hepatitis B and C, or no hepatitis, and there was a 70% male incidence.
Comparisons within Terciles
We then examined the clinical characteristics of patients within tumor size terciles for patterns of heterogeneity after dichotomizing for platelet values <100 × 10 9 /l or ≥ 100 × 10 9 /l ( table 1 a), since thrombocytopenia serves as a surrogate for cirrhosis and subsequent portal hypertension with associated splenomegaly [4] . The subsets of patients with higher platelet values in terciles I (59% of patients) and III (89% of patients) had more normal total bilirubin and prothrombin time (PT) and a slightly larger maximum tumor size, although this was significant only in tercile III. Patients with higher platelet levels also had significantly elevated γ-glutamyl transpeptidase (GGTP) and alkaline phosphatase (ALKP) levels compared to patients with lower platelet levels. These levels occurred in patients with significantly lower bilirubin levels. The AFP levels in each tercile were also elevated in the higher platelet subsets, but with large SD. The low platelet subset of tercile III (11.3% or 39/345 patients) also had large tumors despite thrombocytopenia and elevated bilirubin levels, although the mean tumor diameters were smaller than for patients with normal platelets in the same size tercile.
Comparisons between Tumors in Patients with Similar Platelet Levels
To minimize the confounding effects of differences in liver function, patients in different size terciles, i.e. I and III, but with similar platelet levels, and thus bilirubin levels, were examined ( table 1 b) after re-arranging table 1 a to compare patients within the same platelet dichotomization. Within each platelet dichotomization, tercile III patients with larger tumors had significantly more portal vein thrombosis (PVT) and significantly higher AFP levels than did tercile I patients, as expected. Despite similarities in bilirubin and PT, tercile III patients had significantly higher GGTP and ALKP levels compared to tercile I patients, which is consistent with the idea that GGTP and ALKP levels might be related to tumor size and not just to liver damage. This is clearest for patients with platelets ≥ 100 × 10 9 /l with lower bilirubin levels.
Tercile Subsets and PVT
PVT is considered a poor prognostic factor [2, 3, 9] and often limits therapy choices. Terciles I and III were 
Discussion
Analysis of the clinical practice data is complicated by the heterogeneity of the tumor subsets and the influence of the tumor milieu (underlying liver). Most HCC arise on a background of chronic hepatitis or cirrhosis or both, and prognosis is considered to be related to tumor factors such as serum AFP levels, tumor size and number, and presence of PVT, as well as liver factors, such as portal hypertension and bilirubin levels [9] [10] [11] . There is likely an interaction between them, and both influences were recognized in the classification system of Okuda et al. [12] and subsequently by others, in which greater phenotypic 157 complexity was taken into account. In addition, the nontumoral liver may actually influence HCC biology and have characteristic 'molecular signatures' [13, 14] .
Thrombocytopenia, a surrogate marker for cirrhosis, is associated with subsequent HCC development [2, [15] [16] [17] [18] and smaller HCC [7, 8] . In noncirrhotic livers, HCC tend to be larger [19] [20] [21] [22] , probably since they can grow with less liver damage, whereas HCC growth in cirrhosis is often associated with parenchymal damage. Our larger HCC were associated with higher mean platelet counts, yet patients likely had some degree of fibrosis, as previously shown even in noncirrhotic HCC [20] .
The smaller tumor sizes with thrombocytopenia could reflect cirrhotic liver limiting tumor growth ( fig. 1 ) . However, a tercile III subset of 11.3% of patients (39/345) with thrombocytopenia ( table 1 ) showed that this is an insufficient explanation. In tercile I, 59% (199/336) had higher platelet levels, associated with lower bilirubin and higher AFP with more PVT ( table 1 a). They also had higher GGTP and ALKP levels. Tercile III patients with higher platelet levels (306/345 or 88.6%) had significantly larger tumors, more PVT, higher AFP values (but not significantly), and more normal bilirubin, PT, and albumin values compared to patients with thrombocytopenia. GGTP and ALKP values were higher in both tercile I and III subsets with higher platelet levels and significantly lower bilirubin.
Since the liver milieu is important in HCC biology [13, 14, 19] , we compared size terciles having equivalent platelet levels and thus bilirubin levels ( table 1 b). Tercile III patients had significantly larger tumors, more PVT, and higher AFP, as expected. Despite similar bilirubin, PT, and albumin values, the GGTP and ALKP levels were significantly higher in patients with larger tumors, as previously noted [23] [24] [25] , and this is clearest in tercile III, with high platelet levels and large tumors, although the bilirubin and PT were relatively normal. PVT had no relation to tumor size but was associated with portal hypertension in tercile III. Despite similar tumor sizes, PVT-positive patients in each tercile had significantly higher AFP, GGTP, ALKP, and bilirubin ( table 2 b). The elevated bilirubin levels associated with PVT likely reflect tumor invasion into liver parenchyma.
Two possibilities were considered to explain differences in tumor size in relation to platelets ( fig. 1 ) . Firstly, normal platelets associated with larger tumors may reflect that tumors can grow larger without causing failure in normal livers, but not with portal hypertension [26] , without causing further parenchymal destruction. Thrombocytopenia thus only reflects hepatic fibrosis and portal hypertension and is not directly related to HCC growth. Secondly, platelets have several HCC growth and angiogenesis factors, such as platelet-derived growth factor, vascular endothelial growth factor, fibroblast growth factor, and serotonin [27] [28] [29] [30] [31] [32] [33] [34] [35] , and also facilitate immunemediated liver injury in hepatitis B virus mice, with antiplatelet therapy preventing HCC [36] . Platelets can also produce GGTP and ALKP [37, 38] . Thrombocytosis was reported in 2.7% of a large HCC series in association with large tumors, with platelets >400 × 10 9 /l [39, 40] . There could thus be different pathways for HCC development in the presence or absence of thrombocytopenia. In addition to their role in blood coagulation, platelets might also be involved in HCC growth and could be a novel target for HCC therapies in patients without thrombocytopenia. Thus, platelet-derived blood growth factors might be future markers or predictors of large size.
Conclusions
We previously focused on small HCC size and thrombocytopenia. We have now shown the usefulness of a tercile approach to identifying HCC subsets in a heterogeneous tumor population and also highlight the importance of elevated GGTP levels associated with larger tumors in the absence of increased bilirubin levels.
